Sector News

Raptor Pharmaceutical Appoints Krishna Polu, M.D. as Chief Medical Officer and Michael Smith as Chief Financial Officer

January 8, 2015
Life sciences

(GLOBE NEWSWIRE via COMTEX) – Raptor Pharmaceutical Corp. today announced the appointment of Krishna R. Polu, M.D., as its Chief Medical Officer and Michael P. Smith as Chief Financial Officer, effective January 12, 2015. Dr. Polu will oversee all global clinical development programs, medical affairs and other related functions. Mr. Smith will serve as Raptor’s principal financial and accounting officer. Both will report to Julie Anne Smith, Raptor’s President and Chief Executive Officer.

“We are delighted to welcome Krishna and Michael aboard Raptor’s executive team. Krishna’s impressive experience as a clinical nephrologist, along with his clinical development and regulatory expertise, will help us achieve our research and development goals,” said Ms. Smith. “Michael brings significant knowledge of and proven leadership experience in financial management and corporate development in rapidly growing companies which will be an asset to Raptor as we continue to expand our business.”

Dr. Polu most recently served as Chief Medical Officer at CytomX Therapeutics, a privately-held biotechnology company focused on the development of Probody™ therapeutics, a novel monoclonal antibody platform for the treatment of cancer. Prior to that, he served as Vice President of Clinical Development at Affymax, where he led multiple functions, including clinical sciences, clinical operations and drug safety/pharmacovigilance and was integral to the development and regulatory approval of the company’s first drug, OMONTYS®, a pegylated peptide for the treatment of anemia due to chronic kidney disease. Prior to Affymax, he served as Executive Director of Global Development at Amgen and led late-stage clinical research programs across a wide range of therapeutic areas including nephrology, diabetes and heart failure and executed on several large cardiovascular outcomes trials as well as led the global clinical activities to support commercialization for EPOGEN® and Aranesp®.

Dr. Polu received his B.A. from Stanford University and his M.D. from the University of Texas, San Antonio. In addition, he completed an internal medicine internship and residency at the University of Colorado as well as clinical and research fellowships in nephrology and transplant at Harvard Medical School in a joint program with Brigham and Women’s Hospital and Massachusetts General Hospital.

Michael Smith most recently served as Catalyst Biosciences’ Chief Financial and Business Advisor. Prior to that, he was Vice President of Business Development at iPierian and Chief Financial Officer for Memory Pharmaceuticals where he oversaw all finance, business development, strategic planning, intellectual property and site operation activities. Previously, Mr. Smith was Vice President of Business Development at QLT. At Chiron, he held several positions of increasing responsibility and also established Chiron’s TOBI® franchise for cystic fibrosis. Throughout his career, Mr. Smith has managed and led numerous successful financings and corporate and product acquisitions, as well as strategic partnerships.

Mr. Smith received his B.S. from the University of Virginia and his MBA from the Haas School of Business at the University of California, Berkeley.

Source: Raptor Pharmaceutical

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]